Portal de Periódicos da CAPES

Felodipine extended release in mild to moderate hypertension

1991; Taylor & Francis; Volume: 12; Issue: 5 Linguagem: Inglês

10.1185/03007999109112661

1473-4877

A. Wester, A R Lorimer, Berit Westberg,

Heart Rate Variability and Autonomic Control

SummaryA multi-centre study was carried out to examine the antihypertensive effect and adverse event profile of felodipine in an extended-release (ER) formulation given once daily as monotherapy. Doses of 5 mg, 10 mg or 20 mg felodipine ER were compared with placebo in 183 patients with mild or moderate hypertension. All antihypertensive medication was discontinued on entering a 4-week placebo run-in period. IJ at the end of the run-in period, supine diastolic blood pressure was in the range >95⁢120 mmHg, patients were randomly allocated to double-blind treatment with felodipine, 5 mg, 10 mg or 20 mg, or placebo, to be taken once daily for 4 weeks. Supine and standing blood pressure, heart rate and body weight were measured every 2 weeks during the trial. Assessments were made 24 hours after intake of the study drug. Adverse events were recorded at each review. Over the 4-week treatment period, a dose-related decrease in supine diastolic blood pressure was observed, this reduction occurring already during the first 2 weeks of active treatment. In the placebo group and the felodipine 5 mg, 10 mg and 20 mg groups, supine blood pressure (systolic/diastolic) decreased by 7/6 mmHg, 9/8 mmHg, 12/10 mmHg and 14/11 mmHg, respectively. Supine diastolic blood pressure reduction in the, felodipine 10 mg group and both systolic and diastolic blood pressure reductions in the 20 mg group were significantly greater than with placebo. Standing diastolic blood pressure reduction was significantly greater in all three dose groups on felodipine compared with placebo. There were no differences between treatment groups in heart rate and body weight. The proportion of patients reporting adverse events was similar in the run-in and double-blind periods in the placebo group but increased in all three groups during felodipine therapy. In conclusion, the results showed that the felodipine ER formulation achieved satisfactory 24-hour blood pressure control.